AC-262536 is a selective androgen receptor modulator (SARM) that is currently being researched for its potential use in the treatment of muscle wasting and osteoporosis. The chemical name of AC-262536 is 4-[(2R)-2-[(1R)-2-methyl-1-(phenylmethylamino)propyl]pyrrolidin-1-yl]-2-trifluoromethylbenzonitrile. Its molecular formula is C20H21F3N2 and its formula weight is 352.4 g/mol. AC-262536 has a CAS number of 871032-12-1.
Top Ten Keywords:
Synonyms:
Health Benefits:
AC-262536 is a novel SARM that has potential therapeutic benefits for the treatment of muscle wasting and osteoporosis. It has been shown to have anabolic effects on muscle tissue and bone density, while also lacking the androgenic effects that are associated with other anabolic steroids. However, further research is needed to determine the safety and efficacy of AC-262536 in humans.
Potential Effects:
The potential effects of AC-262536 are related to its activity as a SARM. It has been shown to have anabolic effects on muscle tissue and bone density, which could make it a promising therapeutic agent for the treatment of conditions such as muscle wasting and osteoporosis. Additionally, because it lacks the androgenic effects that are associated with other anabolic steroids, it may have a more favorable safety profile.
Product Mechanism:
AC-262536 works by selectively binding to and activating androgen receptors in muscle tissue and bone. This leads to increased protein synthesis and muscle growth, as well as improved bone density.
Safety:
The safety of AC-262536 has not been fully established, as it is still in the early stages of research. However, because it lacks the androgenic effects that are associated with other anabolic steroids, it may have a more favorable safety profile. Prior to clinical use, further research is needed to determine the safety and efficacy of AC-262536 in humans.
Side Effects:
The side effects of AC-262536 are not fully understood, but may include increased risk of cardiovascular disease, liver damage, and suppression of natural testosterone production. Further research is needed to determine the safety and potential side effects of AC-262536 in humans.
Dosing Information:
The appropriate dosing information for AC-262536 has not been established, as it is still in the early stages of research.
Conclusion:
AC-262536 is a novel SARM that is being investigated for its potential therapeutic benefits in the treatment of muscle wasting and osteoporosis. It has been shown to have anabolic effects on muscle tissue and bone density while lacking the androgenic effects associated with other anabolic steroids. However, further research is needed to determine the safety and efficacy of AC-262536 in humans, including dosing information and potential side effects.
